NCT06777316 2026-04-17
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Cogent Biosciences, Inc.
Phase 1/2 Active not recruiting
Cogent Biosciences, Inc.
Tango Therapeutics, Inc.
Astellas Pharma Inc
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Tango Therapeutics, Inc.